Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golidocitinib + CHOP
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Golidocitinib + CHOP is an investigational combination therapy consisting of golidocitinib, a selective Janus kinase 1 (JAK1) inhibitor, and the standard CHOP chemotherapy regimen. Golidocitinib is a small molecule developed for its targeted inhibition of JAK1, which plays a key role in cytokine signaling pathways involved in hematologic malignancies. The CHOP regimen includes cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), vincristine (a mitotic inhibitor), and prednisone (a corticosteroid). This combination is being explored primarily for the treatment of aggressive lymphomas such as peripheral T-cell lymphoma and diffuse large B-cell lymphoma.
- Brand names
- Xruida
- Other names
- Golidocitinib plus CHOPGolidocitinib + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone
02
Targets
Beyond the preview
Go deeper on golidocitinib + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golidocitinib + CHOP.